This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Gamma glutamyl transpeptidase (gamma GT)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Gamma-glutamyl transpeptidase is an enzyme which is found in hepatocytes and biliary epithelial cells. GGT may be high in liver disease. In particular it is a feature of biliary outflow obstruction rather than hepatocellular damage.

  • GGT (in men) = 11 - 50 i.u./l
  • GGT (in women) = 7 - 32 i.u./l

Note reference ranges may vary between laboratories.

GGT serum measurement provides a very sensitive indicator of the presence or absence of hepatobiliary disease. However the usefulness of measurement of serum GGT is limited by its lack of specificity. Raised GGT levels have been reported in a variety of clinical conditions including (1):

  • pancreatic disease
  • myocardial infarction
  • chronic obstructive pulmonary disease
  • renal failure
  • diabetes
  • obesity
  • alcoholism

Drugs such as phenytoin and barbiturates may cause high GGT levels (1).

.

The linked page GGT in hepatobiliary disease details hepatobiliary causes of a raised GGT.

Reference:

  1. Royal Pharmaceutical Society. Liver function tests: indication and interpretation. Feb 2022 [internet publication].

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.